Clinical Trials · NCT04971785
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Gilead Sciences
- Enrollment
- 457
- Start date
- Aug 2021
- Locations
- 242 sites, 7 countries
- Primary endpoint
- Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups